These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32785655)

  • 1. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
    Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
    Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
    Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
    Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
    Shah SB; Carlson CR; Lai K; Zhong Z; Marsico G; Lee KM; Félix Vélez NE; Abeles EB; Allam M; Hu T; Walter LD; Martin KE; Gandhi K; Butler SD; Puri R; McCleary-Wheeler AL; Tam W; Elemento O; Takata K; Steidl C; Scott DW; Fontan L; Ueno H; Cosgrove BD; Inghirami G; García AJ; Coskun AF; Koff JL; Melnick A; Singh A
    Nat Mater; 2023 Apr; 22(4):511-523. PubMed ID: 36928381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
    Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
    J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma.
    Plotnik JP; Richardson AE; Yang H; Rojas E; Bontcheva V; Dowell C; Parsons S; Wilson A; Ravanmehr V; Will C; Jung P; Zhu H; Partha SK; Panchal SC; Mali RS; Kohlhapp FJ; McClure RA; Ramathal CY; George MD; Jhala M; Elsen NL; Qiu W; Judge RA; Pan C; Mastracchio A; Henderson J; Meulbroek JA; Green MR; Pappano WN
    Mol Cancer Ther; 2024 Jul; 23(7):949-960. PubMed ID: 38507740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
    Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
    J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
    Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
    Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
    Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
    Lim SM; Jeong Y; Lee S; Im H; Tae HS; Kim BG; Park HD; Park J; Hong S
    J Med Chem; 2015 Nov; 58(21):8491-502. PubMed ID: 26496175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
    Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attacking MALT1 for ABC-DLBCL therapy.
    Krappmann D
    Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
    Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
    J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
    Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
    J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.